Gemma Jones
20 posts
Gemma Jones
@ReporterGemma
Senior reporter for @apmhealtheurope covering pharma, biotech, drug R&D, health economics, market access and more. DMs open. Views are my own.
London, England Katılım Ocak 2023
397 Takip Edilen46 Takipçiler
CMS announced today that #Medicare coverage is available for a second monoclonal amyloid beta antibody treatment for #Alzheimer’s Disease. CMS remains committed to helping people with Alzheimer’s get timely access to innovative treatments. Learn more:
go.cms.gov/4btAefn
English
This seems important. FDA removing the change notification letter for Tecartus suggests that it doesn't - yet - see T-cell malignancy risk as a Car-T class effect twitter.com/JacobPlieth/st… $GILD $AUTL
Jacob Plieth@JacobPlieth
@aymansaadOSU @BLLPHD How strange - $GILD Tecartus indeed is no longer on the FDA list
English
Schett group CD19 Car-T therapy for autoimmune disease. Focus on 8 lupus patients, via Fabian Műller #ASH23 $CABA
English
Gemma Jones retweetledi
Babies with a rare genetic condition could receive a potentially curative one-off gene therapy before they develop symptoms.
Our final draft guidance recommends routine NHS funding of Zolgensma for treating spinal muscular atrophy.
Learn more: nice.org.uk/guidance/indev… #NICENews
English
Gemma Jones retweetledi
According to Brian Henry, chair of the #MMIP, the UK could be the "best place in the world" to manufacture new, advanced drugs but it is "currently losing out on investments and exports, as well as jobs, to international competitors". #medicinemanufacturing #innovativemedicines
ABPI@ABPI_UK
🚨Out today - a new paper from the Medicines Manufacturing Industry Partnership on where we are on UK medicines manufacturing and what still needs to be done 🧬💊💉🖥️🧑🤝🧑 abpi.org.uk/media/news/202…
English
I'm excited to follow this one next week - lots to discuss on how to evolve the European regulatory framework for the benefit of patients #innovativemedicines
Reuters Events Pharma@RE_Pharma
How can we align Europe's regulatory frameworks for #innovativemedicines with new legislation review? Leaders at @EMA_News @EU_Commission @Europarl_EN @EFPIA will discuss with Journalist and Speaker on EU Affairs, Jacki Davis. Register here events.reutersevents.com/innovativemedi… #WeWontRest
English
It was great to chat with @CellProthera's CEO Matthieu de Kalbermatten earlier. With stem cells derived from the patient's own blood, the French #biotech is working to develop a product that will allow a heart damaged by a heart attack to regenerate. One to watch.
English
According to the report, the "overarching challenge" is to "ensure that health and care system leaders position medicines as a strategic enabler of improved patient outcomes, NHS productivity and efficiencies across the system as well as a clinical intervention for individuals".
English
"Adoption of innovation is challenged by the fact that NHS leaders face ongoing operational pressures every day – asked to meet increasing demand, reduce health inequalities and improve outcomes within constrained resources, while also trying to re-imagine services [...]."
English
Really interesting report from @ABPI_UK and #NHS Confederation on variations in access to innovative medicines for patients in the #UK, with report data showing a 51% variation of uptake of 3 types of #diabetes medicines between NHS trusts in England nhsconfed.org/publications/t…
English
This will be a good one to watch given the rising global #cancer care demand and the difficulties faced by healthcare systems due to resource constraints @EFPIA
Financial Times Live@ftlive
Smart investments in cancer care are urgently needed to alleviate demands on healthcare systems. Next week, join us to discuss the many innovative ways that are emerging to make cancer care more resilient. In partnership with @EFPIA. Register for free cancercare.live.ft.com
English
“The industry is clear that if the UK cannot address rapidly escalating rates […], the government’s Life Sciences Vision will be unachievable and the UK will increasingly see investment, jobs & research partnerships going to more supportive markets in the US, Europe & Asia.”
English
Looking forward to interviewing key experts from @Phacilitate’s #AdvancedTherapiesWeek to learn all about the latest developments in the space. I have a few more slots available so please don’t hesitate to reach out. It would be great to connect with some old and new faces #ATW23
English
Gemma Jones retweetledi
Our 2023 #EUPharmaStrategy legislation revision aims to:
🔸stimulate innovation
🔸address unmet medical needs
🔸support a competitive European pharma industry
🔸promote high global standards for medicines
#HealthUnion
Sandra Gallina@SandraGallina
Gli obiettivi della revisione della legislazione farmaceutica europea 2023 #EUPharmaStrategy 🔸stimolare innovazione e competitività 🔸rispondere alle esigenze mediche insoddisfatte 🔸promuovere standard a livello mondiale. europa.eu/!9JgKcb #HealthUnion
English
Gemma Jones retweetledi
Gemma Jones retweetledi
We’re delighted to welcome our latest member @moderna_tx, a company investing heavily in the 🇬🇧 abpi.org.uk/media/news/202…
English
Great to hear @ABPI_UK's @jnharris1189 speak at yesterday's @WHEFEvents conference on how the UK needs to "turbocharge" its research and innovation ecosystem to attract international mobile investment and achieve #sciencesuperpower status
English
Lots of food for thought from today’s @WHEFEvents conference on priorities for #UK research and innovation. Particularly enjoyed discussions led by @baroness_brown on the UK’s ‘scientific superpower’ ambitions and the potential risks of it becoming just an “empty slogan”.
English